Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
| (Q3)Feb 28, 2026 | (Q2)Nov 30, 2025 | (Q1)Aug 31, 2025 | (FY)May 31, 2025 | (Q4)May 31, 2025 | (Q3)Feb 28, 2025 | (Q2)Nov 30, 2024 | (Q1)Aug 31, 2024 | (FY)May 31, 2024 | (Q4)May 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -35.35%-4.35M | -26.59%-3M | -31.38%-2.61M | -109.12%-11.31M | -120.06%-3.73M | -171.65%-3.22M | -83.22%-2.37M | -61.15%-1.98M | 4.82%-5.41M | -0.47%-1.7M |
| Net income from continuing operations | -10.24%-4.41M | 12.96%-3.32M | -80.77%-2.92M | -98.86%-14.16M | -103.92%-4.73M | -199.59%-4M | -114.82%-3.82M | 4.35%-1.62M | 16.21%-7.12M | 11.38%-2.32M |
| Operating gains losses | -99.79%482 | -87.01%38K | 94.40%-4.58K | 802.11%252.21K | -644.34%-191.99K | 5,414.09%233.5K | 1,030.09%292.51K | -184.05%-81.81K | -95.90%27.96K | 10,659.88%35.27K |
| Depreciation and amortization | -6.75%3.6K | -7.64%3.37K | 0.25%3.2K | 13.93%14.68K | 12.68%3.97K | 19.14%3.87K | 18.73%3.65K | 4.96%3.2K | -23.29%12.89K | -21.18%3.53K |
| Asset impairment expenditure | ---- | ---- | ---- | --0 | --0 | --0 | --0 | --0 | -58.18%189.03K | --0 |
| Remuneration paid in stock | -43.17%262.37K | -68.91%190.57K | --325.96K | 738.66%1.62M | 50,171.18%549.46K | 4,866.84%461.67K | 966.19%612.9K | --0 | -64.71%193.65K | -99.50%1.09K |
| Other non cashItems | -138.45%-56.33K | -33.73%145.09K | 17.60%251.77K | -18.44%646.68K | -67.59%67.12K | -25.45%146.53K | 12.90%218.95K | 9.64%214.08K | -38.85%792.86K | -54.56%207.12K |
| Change In working capital | -141.10%-158.1K | -117.46%-55.65K | 48.24%-260.32K | -36.00%319.61K | 51.19%569.37K | -19.74%-65.58K | 86.40%318.7K | -7,719.52%-502.89K | 383.67%499.41K | 286.00%376.6K |
| -Change in receivables | 82.98%87.95K | -62.27%-90.79K | -1,152.26%-40.35K | -190.05%-9.65K | -4.73%-5.6K | 819.57%48.07K | -377.60%-55.95K | 141.14%3.84K | 433.90%10.72K | 65.74%-5.35K |
| -Change in prepaid assets | -45.53%-111.16K | -2,503.44%-71.2K | -618.69%-36.28K | -135.05%-43.03K | 162.86%29.09K | -396.08%-76.38K | -102.92%-2.74K | -92.30%6.99K | 233.57%122.77K | 64.82%-46.28K |
| -Change in payables and accrued expense | -262.02%-134.89K | -71.82%106.35K | 64.24%-183.68K | 1.74%372.29K | 27.48%545.88K | 16.45%-37.26K | 560.26%377.39K | -586.24%-513.72K | 552.18%365.93K | 873.85%428.22K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -35.35%-4.35M | -26.59%-3M | -31.38%-2.61M | -109.12%-11.31M | -120.06%-3.73M | -171.65%-3.22M | -83.22%-2.37M | -61.15%-1.98M | 4.82%-5.41M | -0.47%-1.7M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -1.74%-9.55M | -125,806.13%-2.14M | -815.52%-73.22K | -6,851.37%-9.4M | 52.55%-2.95K | -23,291.99%-9.39M | -103.81%-1.7K | 96.26%-8K | 97.41%-135.23K | 99.82%-6.21K |
| Net PPE purchase and sale | 62.98%-1.13K | --0 | 90.47%-762 | -19.35%-15.68K | 45.79%-2.95K | 49.85%-3.04K | ---1.7K | -387.68%-8K | 98.91%-13.14K | ---5.43K |
| Net business purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Net investment purchase and sale | -100.00%-10M | --33.04K | --2.09M | ---5M | --0 | ---5M | --0 | --0 | --0 | --0 |
| Net other investing changes | ---- | ---2.17M | ---2.16M | -3,491.22%-4.38M | ---- | ---- | ---- | ---- | 96.95%-122.09K | ---170.72K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -1.74%-9.55M | -125,806.13%-2.14M | -815.52%-73.22K | -6,851.37%-9.4M | 52.55%-2.95K | -23,291.99%-9.39M | -103.81%-1.7K | 96.26%-8K | 97.41%-135.23K | 99.82%-6.21K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 1,968.58%19.11M | -75.75%4.7M | 422.55%1.41M | 332.19%24.99M | -23.90%4.4M | 923.61K | 19.4M | 269.23K | -52.43%5.78M | -29.84%5.78M |
| Net issuance payments of debt | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | --0 |
| Net common stock issuance | --20M | ---- | ---- | 289.61%15M | --0 | --0 | ---- | ---- | -68.93%3.85M | -53.31%3.85M |
| Proceeds from stock option exercised by employees | -40.29%551.48K | -4.95%4.71M | 423.89%1.41M | 390.07%10.55M | 104.53%4.4M | --923.61K | --4.95M | --269.23K | 83.27%2.15M | 180.62%2.15M |
| Net other financing activities | ---1.45M | ---3.94K | ---3.59K | -153.17%-556.41K | ---2.04K | --0 | ---- | ---- | 62.97%-219.78K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 1,968.58%19.11M | -75.75%4.7M | 422.55%1.41M | 332.19%24.99M | -23.90%4.4M | --923.61K | --19.4M | --269.23K | -52.43%5.78M | -29.84%5.78M |
| Net cash flow | ||||||||||
| Beginning cash position | -64.80%6.91M | 181.64%7.35M | 98.98%8.62M | 5.91%4.33M | 3,072.68%7.95M | 1,307.95%19.63M | -1.37%2.61M | 5.91%4.33M | 44.66%4.09M | -74.96%250.68K |
| Current changes in cash | 144.52%5.2M | -102.55%-433.92K | 26.09%-1.27M | 1,675.07%4.29M | -83.69%665.55K | -921.21%-11.68M | 1,462.49%17.03M | -19.22%-1.72M | -80.89%241.53K | 32.07%4.08M |
| Cash adjustments other than cash changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| End cash Position | 52.29%12.11M | -64.80%6.91M | 181.64%7.35M | 98.98%8.62M | 98.98%8.62M | 3,072.68%7.95M | 1,307.95%19.63M | -1.37%2.61M | 5.91%4.33M | 5.91%4.33M |
| Free cash from | -35.25%-4.36M | -26.50%-3M | -30.89%-2.61M | -108.91%-11.32M | -119.54%-3.74M | -170.53%-3.22M | -83.35%-2.37M | -61.58%-1.99M | 21.30%-5.42M | -0.79%-1.7M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.